Filing Analysis
Evolus, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- The filing is related to the quarter ended June 30, 2026.
- Financial results were announced via press release on August 5, 2026.
- The report was signed by David Moatazedi, President and Chief Executive Officer.
Evolus, Inc. (via its subsidiary Evolus Europe) has amended its license agreement with Symatese Aesthetics S.A.S. to expand the commercialization and distribution rights of Estyme® branded injectable hyaluronic acid gels into Canada, Australia, and New Zealand.
📋 Key Facts
- Amendment dated August 3, 2026, expands territory to include Canada and combined Australia/New Zealand.
- Evolus Europe granted exclusive rights to commercialize and distribute Estyme® branded injectable hyaluronic acid gels in these new territories.
- Upfront signing payment of €920,000 required.
- Contingent milestone payments up to an additional €1.38 million upon receipt of regulatory approvals.
- Symatese is responsible for all development and regulatory costs in the new territories.
- Initial term for new territories is 15 years from first applicable regulatory approval, with automatic five-year renewals.
Evolus, Inc. has entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA to develop, commercialize, and distribute Profhilo® in the United States. The agreement grants Evolus rights to the injectable hyaluronic acid product for aesthetics and dermatological use following FDA approval.
🚩 Red Flags
- Minimum purchase requirements starting in year 4 post-launch create a potential liability if commercial adoption is slower than expected.
- Failure to meet minimums could lead to loss of exclusivity or contract termination.
📋 Key Facts
- Agreement entered into on July 7, 2026, with IBSA Institut Biochimique SA.
- Exclusive rights in the U.S. to develop, commercialize, and distribute Profhilo® for skin-quality applications.
- Evolus is responsible for all costs related to U.S. development, clinical, and regulatory activities required for FDA approval.
- Post-FDA approval, Evolus will purchase products from IBSA under a transfer-price model.
- Agreement includes minimum purchase requirements starting in the 4th year post-commercial launch; failure to meet these may result in loss of exclusivity or termination.
- No upfront or milestone payments are required by Evolus.
- Initial term is 15 years from first FDA approval, with optional five-year renewals.
Evolus, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected two Class II directors, ratified the appointment of Ernst & Young LLP as independent auditors, and approved executive compensation on an advisory basis.
🚩 Red Flags
- Significant 'Withhold' votes for director Vikram Malik (18,831,201 votes) compared to Brady Stewart (1,662,228 votes), suggesting potential stockholder dissatisfaction with specific board members.
📋 Key Facts
- Annual Meeting of Stockholders held on June 11, 2026.
- Brady Stewart and Vikram Malik were elected as Class II directors for three-year terms ending in 2029.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Executive compensation for named executive officers was approved on an advisory basis.
Evolus, Inc. reported its Q1 2026 financial results and announced the termination of its $50 million at-the-market (ATM) equity offering facility. The company had not utilized the facility to sell any shares since its inception in March 2023.
📋 Key Facts
- Released Q1 2026 financial results for the period ended March 31, 2026.
- Terminated the Sales Agreement with Leerink Partners LLC (formerly SVB Securities LLC) effective May 1, 2026.
- The Sales Agreement provided for the potential sale of up to $50.0 million of common stock.
- Confirmed that zero shares were sold under the ATM agreement prior to its termination.
Evolus, Inc. rebalanced its board of directors by reclassifying Chairman Vikram Malik from Class III to Class II following a previous director's departure. The move was a technical resignation and reappointment to maintain equal class distribution under the company's classified board structure.
📋 Key Facts
- Vikram Malik reclassified from Class III to Class II director on March 13, 2026
- Action follows the previous departure of director Simone Blank to support board refreshment efforts
- Malik resigned and was immediately reappointed to ensure continuous and uninterrupted service
- Malik remains Chairman of the Board and a member of the Compensation Committee
- The Board now consists of six directors, with two directors in each of the three classes
- No new equity awards were granted in connection with this reclassification
Evolus, Inc. entered into a new $30 million senior secured asset-based revolving credit facility with Eclipse Business Capital LLC, maturing in March 2029. The facility is secured by substantially all of the company's assets and was announced alongside the company's Q4 and full-year 2025 financial results.
🚩 Red Flags
- The $10.0 million minimum utilization requirement forces the company to carry debt and incur interest costs regardless of immediate cash needs.
- Substantially all company assets are pledged as collateral to secure the facility.
- High prepayment penalties (up to 3%) restrict refinancing flexibility in the near term.
📋 Key Facts
- The Revolving Credit Facility provides up to $30.0 million, subject to a borrowing base of eligible accounts receivable and inventory.
- Includes an uncommitted accordion feature for an additional $10.0 million.
- The facility carries a minimum utilization requirement of $10.0 million.
- Interest rate is set at adjusted SOFR (minimum 2.0% floor) plus a 4.25% margin.
- The agreement matures on March 3, 2029, and includes a 1.0% closing fee.
- Prepayment fees are 3.0% in the first year and 2.0% in the second year.
Evolus, Inc. issued an 8-K to announce the release of preliminary, unaudited net revenue and other operational/financial data for the quarter and fiscal year ended December 31, 2025.
📋 Key Facts
- Report date: January 9, 2026
- Reporting period: Quarter and Year ended December 31, 2025
- Content: Preliminary, unaudited net revenue and operational/financial data
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Evolus, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's recent operating performance.
📋 Key Facts
- The filing relates to financial results for the quarter ended September 30, 2025.
- Results were announced via press release on November 5, 2025.
- The report was signed by David Moatazedi, President and CEO.
Evolus, Inc. announced the appointment of Tatjana Mitchell as the new Chief Financial Officer, effective September 8, 2025. The filing details her compensation package, including a base salary and significant equity inducement grants.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Tatjana Mitchell appointed as CFO effective September 8, 2025.
- Base salary set at an annualized rate of $490,000.
- One-time signing bonus of $100,000 with a clawback provision if employment ends within two years.
- Target annual bonus opportunity is 55% of base salary.
- Equity compensation includes stock options and RSUs valued at $750,000 each (totaling $1.5M in value) as inducement grants.
- Severance package includes 12 months of salary plus COBRA coverage if terminated without cause; increases to 18 months in a change-in-control scenario.
Evolus, Inc. announced the appointment of CEO David Moatazedi as interim Principal Financial Officer and the departure of Chief Marketing Officer Tomoko Yamagishi-Dressler, effective August 22, 2025.
🚩 Red Flags
- Dual role for CEO: The President and CEO is assuming the PFO/CFO responsibilities, which can indicate a gap in senior leadership or internal control transitions.
- Departure of a key C-suite officer (CMO) during a period of financial reporting.
📋 Key Facts
- CEO David Moatazedi appointed to serve as Principal Financial Officer until a successor is found (effective Aug 1, 2025).
- CMO Tomoko Yamagishi-Dressler departing effective August 22, 2025.
- The CMO departure was mutually agreed upon and not due to any disagreement regarding operations or policies.
- The company released its Q2 2025 financial results (quarter ended June 30, 2025) via press release.
Evolus, Inc. reported the voluntary resignation of Simone Blank from its Board of Directors as part of a planned refreshment strategy. The filing also details results from the company's Annual Meeting of Stockholders, including director elections and auditor ratification.
🚩 Red Flags
- None identified; departure is characterized as voluntary and part of a planned transition.
📋 Key Facts
- Simone Blank voluntarily stepped down from the Board effective June 5, 2025.
- The departure was part of a planned board refreshment; no disagreements with the company were reported.
- Albert White III will serve on the Audit Committee following Ms. Blank's departure.
- David Gill and Albert White III were elected as Class I Directors for three-year terms ending in 2028.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay).
- Annual Meeting held on June 5, 2025.
Evolus, Inc. announced the voluntary resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025. The company stated the departure is to pursue another opportunity and was not due to any disagreements regarding operations, policies, or accounting practices.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO) can create short-term operational uncertainty and transition risk.
📋 Key Facts
- Sandra Beaver is resigning from her position as CFO.
- The resignation is voluntary and effective June 13, 2025.
- Resignation announced on May 27, 2025; notice given on May 23, 2025.
- Company explicitly states there were no disagreements regarding accounting principles or financial disclosures.
Evolus, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025 via a press release.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2025.
- Filing date: May 7, 2025.
- The financial results are provided in Exhibit 99.1 as a press release.
Evolus, Inc. entered into an amended and restated loan agreement to refinance existing debt and provide up to $250 million in new term loans via three tranches. The facility is secured by substantially all of the company's personal property and assets.
🚩 Red Flags
- Significant debt refinancing/refinancing requirement suggests need for liquidity management.
- High interest rate environment (SOFR + 5%) indicates higher cost of capital typical of private credit/non-bank lenders.
- Collateralization: Lenders have a security interest in substantially all company assets.
📋 Key Facts
- Entered into A&R Loan Agreement with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP on May 5, 2025.
- Total aggregate principal amount up to $250,000,000, structured in three tranches: Tranche A ($150M), Tranche B (up to $50M), and Tranche C (up to $50M).
- Tranche A is available on the effective date; Tranches B and C are at the Company's election.
- Interest rate: 3-month SOFR + 5.0% per annum (with a SOFR floor of 3.50%).
- Maturity: 5 years from the Tranche A Closing Date.
- Security: Substantially all personal property, rights, and assets of the Company are pledged as collateral.
- Prepayment terms include an exit consideration of 2% and a sliding scale prepayment premium (3% down to 0.5%) depending on timing.
Evolus, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2024. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Report date: March 4, 2025
- Reporting period: Quarter and year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Evolus, Inc. issued an 8-K to announce the release of preliminary, unaudited net revenue and other operational/financial data for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: January 21, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- Content: Preliminary, unaudited net revenue and operational/financial data
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Evolus, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2024. The filing serves as a formal notification that financial results have been released via Exhibit 99.1.
📋 Key Facts
- The company issued a press release on November 6, 2024, regarding its Q3 2024 financial results.
- Financial results cover the quarter ended September 30, 2024.
- The filing is made pursuant to Item 2.02 of Form 8-K (Results of Operations and Financial Condition).
Evolus, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- The report date is July 31, 2024.
- The filing pertains to financial results for the quarter ended June 30, 2024.
- A press release containing the financial results was issued as Exhibit 99.1.
Evolus, Inc. announced a planned board refreshment involving the appointment of Albert G. White III to the Board and Regulatory and Compliance Committee, alongside the voluntary departure of Robert Hayman.
🚩 Red Flags
- None identified; departures were described as voluntary and part of a 'planned board refreshment'.
📋 Key Facts
- Albert G. White III appointed as Class I director effective July 1, 2024.
- Mr. White will serve on the Regulatory and Compliance Committee; he is deemed an independent director.
- Compensation for Mr. White includes ~$255,000 in RSUs vesting over two years (50% in 2025, 50% in 2026) and a $50,000 annual retainer.
- Robert Hayman voluntarily stepped down from the Board effective July 1, 2024, as part of planned board refreshment.
- David Gill will now serve as the Chairman of the Compensation Committee following Mr. Hayman's departure.
Evolus, Inc. reported the results of its Annual Meeting of Stockholders held on June 6, 2024. The meeting included the election of three Class III Directors and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Stockholders elected David Moatazedi, Vikram Malik, and Karah Parschauer to the Board of Directors for terms ending in 2027.
- Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
- The 2024 Employee Stock Purchase Plan (ESPP) was approved and became effective on June 6, 2024.
- Stockholders approved executive compensation on an advisory basis.
- Stockholders voted for a 1-year frequency for future advisory votes on executive compensation.
Evolus, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024 via a press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is primarily to furnish Exhibit 99.1 (Press Release) containing financial results.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Evolus, Inc. announced the planned departures of two Board members, Robert Hayman and Simone Blank, as part of a board refreshment initiative. Both directors stated their transitions are not due to any disagreements with the company's operations or policies.
📋 Key Facts
- Robert Hayman will step down upon the identification and appointment of a replacement director.
- Simone Blank will step down at either the 2025 Annual Shareholder Meeting or upon the appointment of a replacement, whichever occurs first.
- The departures are part of 'Board refreshment efforts'.
- Neither departure is related to any disagreement with company operations, policies, or practices.
Evolus, Inc. completed a public offering of 3,554,000 shares of common stock at $14.07 per share. The company expects to receive approximately $46.9 million in net proceeds to fund product growth and business development.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common stock.
📋 Key Facts
- Offered 3,554,000 firm shares at a public price of $14.07 per share.
- Underwriters purchased shares at a price of $13.2258 per share.
- Underwriters hold an option to purchase up to 533,100 additional shares (the 'Option').
- Estimated net proceeds are approximately $46.9 million, potentially increasing to $54.1 million if the Option is fully exercised.
- Lock-up agreements prohibit certain insiders from selling securities for 60 days from March 11, 2024.
- Proceeds are earmarked for Jeuveau® growth, Evolysse™ launch activities, and business development.
Evolus, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ending December 31, 2023. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- The filing reports financial results for the quarter and year ended December 31, 2023.
- Results were announced via press release on March 7, 2024.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Evolus, Inc. issued a press release announcing preliminary, unaudited net revenue and other operational/financial data for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: January 16, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- Nature of announcement: Preliminary, unaudited net revenue and operational/financial data
- The information is furnished under Item 2.02 and is not considered 'filed' for liability purposes under Section 18.